Reducing blood loss during surgery for large meningiomas using tranexamic acid
Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Brain Meningioma Resections: Study Protocol of a Randomised Controlled Trial
NA · Beijing Tiantan Hospital · NCT05230381
This study is testing if giving tranexamic acid during surgery for large brain tumors can help reduce blood loss for patients having this procedure.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 228 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Beijing Tiantan Hospital (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05230381 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of tranexamic acid in reducing intraoperative blood loss during the resection of large meningiomas, which are brain tumors. Patients undergoing elective surgery for meningiomas larger than 5 cm will receive either a continuous infusion, a single infusion of tranexamic acid, or a placebo. The study aims to determine if tranexamic acid can significantly decrease the average blood loss, which is typically over 1000 ml in these procedures. By focusing on a specific neurosurgical population, this research seeks to fill a gap in existing literature regarding the use of tranexamic acid in neurosurgery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 undergoing elective surgery for supratentorial meningiomas larger than 5 cm.
Not a fit: Patients with allergies to tranexamic acid, a history of thrombotic disease, chronic kidney disease, or those on anticoagulation treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to reduced blood loss during surgery, shorter hospital stays, and improved patient outcomes.
How similar studies have performed: Previous studies have shown that tranexamic acid can effectively reduce blood loss in other surgical contexts, but its application in neurosurgery remains less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing elective supratentorial meningioma resection with estimated tumor diameter \>5cm on brain image. * Age between 18-65 years. * American Society of Anaesthesiologist (ASA) physical status Ⅰ to Ⅲ * Obtain written informed consent. Exclusion Criteria: * Allergic to tranexamic acid. * History of thrombotic disease. * History of chronic kidney disease * Receiving other anticoagulation or antiplatelet treatment. * Refuse to provide written informed consent
Where this trial is running
Beijing, Beijing
- Beijing Tiantan Hospital, Capital Medical University — Beijing, Beijing, China (RECRUITING)
Study contacts
- Principal investigator: Shu Li, M.D. — Beijing Tiantan Hospital
- Study coordinator: Shu Li, M.D.
- Email: lishu@bjtth.org
- Phone: 8613699223065
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Tranexamic Acid, Intraoperative Blood Loss, Meningioma